JPWO2020033129A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020033129A5 JPWO2020033129A5 JP2021506492A JP2021506492A JPWO2020033129A5 JP WO2020033129 A5 JPWO2020033129 A5 JP WO2020033129A5 JP 2021506492 A JP2021506492 A JP 2021506492A JP 2021506492 A JP2021506492 A JP 2021506492A JP WO2020033129 A5 JPWO2020033129 A5 JP WO2020033129A5
- Authority
- JP
- Japan
- Prior art keywords
- component
- car
- payload drug
- drug
- payload
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940079593 drug Drugs 0.000 claims description 42
- 239000003814 drug Substances 0.000 claims description 42
- 239000003446 ligand Substances 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 37
- 230000008685 targeting Effects 0.000 claims description 19
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims description 13
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims description 13
- 108010015832 Non-Receptor Type 2 Protein Tyrosine Phosphatase Proteins 0.000 claims description 9
- 102100033141 Tyrosine-protein phosphatase non-receptor type 2 Human genes 0.000 claims description 9
- 229940122907 Phosphatase inhibitor Drugs 0.000 claims description 8
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 7
- 102000008236 Toll-Like Receptor 7 Human genes 0.000 claims description 6
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 claims description 6
- 239000000556 agonist Substances 0.000 claims description 6
- 102000006815 folate receptor Human genes 0.000 claims description 6
- 108020005243 folate receptor Proteins 0.000 claims description 6
- 102000005962 receptors Human genes 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- 229940044665 STING agonist Drugs 0.000 claims description 5
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 claims description 5
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 claims description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 5
- 102000010451 Folate receptor alpha Human genes 0.000 claims description 4
- 108050001931 Folate receptor alpha Proteins 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N Folic acid Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- 101000617285 Homo sapiens Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 claims description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 4
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 4
- 235000019152 folic acid Nutrition 0.000 claims description 4
- 239000011724 folic acid Substances 0.000 claims description 4
- 229960000304 folic acid Drugs 0.000 claims description 4
- 125000003929 folic acid group Chemical group 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 230000037361 pathway Effects 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 230000003716 rejuvenation Effects 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- 125000006850 spacer group Chemical group 0.000 claims description 4
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 238000004873 anchoring Methods 0.000 claims description 2
- 210000000172 cytosol Anatomy 0.000 claims description 2
- 210000001163 endosome Anatomy 0.000 claims description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- -1 DGKα Proteins 0.000 claims 1
- 102100022735 Diacylglycerol kinase alpha Human genes 0.000 claims 1
- 101710181033 Diacylglycerol kinase alpha Proteins 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862715666P | 2018-08-07 | 2018-08-07 | |
| US62/715,666 | 2018-08-07 | ||
| PCT/US2019/042726 WO2020033129A1 (en) | 2018-08-07 | 2019-07-21 | Rejuvenation of car t cell |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021533166A JP2021533166A (ja) | 2021-12-02 |
| JP2021533166A5 JP2021533166A5 (https=) | 2022-07-28 |
| JPWO2020033129A5 true JPWO2020033129A5 (https=) | 2022-07-28 |
| JP7623935B2 JP7623935B2 (ja) | 2025-01-29 |
Family
ID=69415080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021506492A Active JP7623935B2 (ja) | 2018-08-07 | 2019-07-21 | Ｃａｒ ｔ細胞の若返り |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20210308267A1 (https=) |
| EP (1) | EP3833400A4 (https=) |
| JP (1) | JP7623935B2 (https=) |
| KR (1) | KR20210042125A (https=) |
| CN (2) | CN112543651B (https=) |
| AU (1) | AU2019317278B2 (https=) |
| CA (1) | CA3108710A1 (https=) |
| SG (1) | SG11202100616VA (https=) |
| WO (1) | WO2020033129A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための組成物および方法 |
| JP7549303B2 (ja) | 2018-01-22 | 2024-09-11 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞の使用方法 |
| CN112105382A (zh) | 2018-02-23 | 2020-12-18 | 恩多塞特公司 | 用于car t细胞疗法的顺序方法 |
| CN112262214A (zh) | 2018-04-12 | 2021-01-22 | 优莫佳生物制药股份有限公司 | 病毒载体及包装细胞系 |
| AU2021217003A1 (en) | 2020-02-04 | 2022-09-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Anti-dinitrophenol chimeric antigen receptors |
| US20240058458A1 (en) * | 2020-03-06 | 2024-02-22 | Purdue Research Foundation | Methods, compounds, and compositions for modifying car-t cell activity |
| CN116096861A (zh) * | 2020-04-03 | 2023-05-09 | 赛立维公司 | 过继性细胞转移的增强 |
| US20240293456A1 (en) * | 2020-11-30 | 2024-09-05 | Purdue Research Foundation | Combinations of small molecule drug conjugate and car-expressing cytotoxic lymphocytes and methods of treating cancer using the same |
| US20240390505A1 (en) * | 2021-08-30 | 2024-11-28 | Purdue Research Foundation | Conjugates, compositions, and methods for rejuvenation of car t-cells |
| JP2025506652A (ja) * | 2022-02-18 | 2025-03-13 | エフ． ホフマン－ラ ロシュ アーゲー | 試料中の目的の分析物を検出するための方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8933197B2 (en) * | 2007-08-15 | 2015-01-13 | Amunix Operating Inc. | Compositions comprising modified biologically active polypeptides |
| KR102339240B1 (ko) * | 2013-10-15 | 2021-12-15 | 더 스크립스 리서치 인스티튜트 | 펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도 |
| EP3057991B8 (en) * | 2013-10-15 | 2019-09-04 | The Scripps Research Institute | Chimeric antigen receptor t cell switches and uses thereof |
| ES2918501T3 (es) * | 2013-12-19 | 2022-07-18 | Novartis Ag | Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos |
| WO2015092024A2 (en) * | 2013-12-20 | 2015-06-25 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
| EP3593812A3 (en) * | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| KR20160145802A (ko) * | 2014-04-23 | 2016-12-20 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 요법에 사용하기 위한 키메라 항원 수용체 (car) 및 이의 제조 방법 |
| US20180243340A1 (en) * | 2015-08-24 | 2018-08-30 | University Of Houston System | Combination therapy combining car + t cells with appropriately timed immunodulatory antibodies |
| CN109415687A (zh) * | 2016-04-07 | 2019-03-01 | 蓝鸟生物公司 | 嵌合抗原受体t细胞组合物 |
| JP7282521B2 (ja) * | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| WO2017205661A1 (en) * | 2016-05-25 | 2017-11-30 | Purdue Research Foundation | Method of treating cancer by targeting myeloid-derived suppressor cells |
| CN116474108A (zh) * | 2016-12-14 | 2023-07-25 | 普渡研究基金会 | 成纤维细胞活化蛋白(fap)-靶向成像和治疗 |
| CN110662839A (zh) * | 2017-02-17 | 2020-01-07 | 珀杜研究基金会 | 用于细胞疗法的基于靶向性配体-有效负载的药物递送 |
-
2019
- 2019-07-21 KR KR1020217006445A patent/KR20210042125A/ko not_active Ceased
- 2019-07-21 WO PCT/US2019/042726 patent/WO2020033129A1/en not_active Ceased
- 2019-07-21 CN CN201980052586.7A patent/CN112543651B/zh active Active
- 2019-07-21 US US17/266,509 patent/US20210308267A1/en not_active Abandoned
- 2019-07-21 CA CA3108710A patent/CA3108710A1/en active Pending
- 2019-07-21 EP EP19847190.6A patent/EP3833400A4/en active Pending
- 2019-07-21 JP JP2021506492A patent/JP7623935B2/ja active Active
- 2019-07-21 SG SG11202100616VA patent/SG11202100616VA/en unknown
- 2019-07-21 CN CN202310525133.XA patent/CN116763943A/zh active Pending
- 2019-07-21 AU AU2019317278A patent/AU2019317278B2/en active Active
-
2023
- 2023-12-21 US US18/392,939 patent/US20240148880A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021533166A5 (https=) | ||
| JPWO2020033129A5 (https=) | ||
| Shih et al. | Monoubiquitin carries a novel internalization signal that is appended to activated receptors | |
| Ramello et al. | An immunoproteomic approach to characterize the CAR interactome and signalosome | |
| KR102659574B1 (ko) | 모듈 폴리펩타이드 라이브러리 및 이의 제조 및 사용 방법 | |
| AU2020200414A1 (en) | Microfluidic devices and methods for use thereof in multicellular assays of secretion | |
| EP3661962A1 (en) | Antibodies with functional domains in the elbow region between variable and constant domain | |
| RS62471B1 (sr) | Metode, kompleti i uređaji za proširenje populacije ćelija | |
| CA2936352A1 (en) | Cellular platform for rapid and comprehensive t-cell immunomonitoring | |
| CN105873945A (zh) | 工程化的高亲和力人类t细胞受体 | |
| WO2005116072A3 (en) | Antibodies as t cell receptor mimics, methods of production and uses thereof | |
| CA2504670A1 (en) | Combinatorial libraries of monomer domains | |
| CA2482967A1 (en) | Binary or polynary targeting and uses thereof | |
| EP1319950A1 (en) | Matrix screening method | |
| JP2008500950A (ja) | プロテオーム解析のための膜蛋白質ライブラリー及びその調製方法 | |
| EP3011061B1 (en) | Virion display array for profiling functions and interactions of human membrane proteins | |
| AU2008206462A1 (en) | Combinatorial libraries of conformationally constrained polypeptide sequences | |
| CA3100112A1 (en) | Engineering b lymphocytes by utilizing endogenous activation-induced cytidine deaminase | |
| JP2023552748A (ja) | 細胞表面タンパク質を提示する生物学的小胞及びそれに関連する方法 | |
| CN115997020A (zh) | 新的核酸配体及其鉴定方法 | |
| WO2003062444A3 (en) | Array systems and methods | |
| DE60130211T2 (de) | Matrix-screening-verfahren | |
| WO2023274368A1 (zh) | 基于细胞粘连作用的膜蛋白相互作用筛选平台 | |
| JP2009278927A (ja) | Ｔ細胞受容体を模倣する抗体断片及びその製造方法 | |
| Thammawong et al. | Twin-arginine signal peptide attributes effective display of CD147 to filamentous phage |